Skip to main content
. 2017 May 2;12(5):e0176589. doi: 10.1371/journal.pone.0176589

Table 3. Characteristics of analgesia and side effect.

R25 (n = 23) MR (n = 25) R375 (n = 22) P value
Number requiring rescue analgesic: N 21/23 20/25 19/22 0.532
Consumption of tramadol(0-24h) 50[50,100] 50[0,50] * 50[50,50] * 0.000
Consumption of tramadol(0-48h) 100[50,100] 50[50,75] * 100[50,100] 0.000
AUC-rest (0-24h) cm.h 57.7±9.1 55.4±9.9 57.5±8.2 0.000
AUC-rest (0-48h) cm.h 133.6±16.4 129.5±18.1 132.1±17.6 0.001
AUC-evoked (0-24h) cm.h 96.6±12.6 85.2±9.0 * 77.7±10.8 * 0.000
AUC-evoked (0-48h) cm.h 206.7±25.4 192.4±21.5 191.2±24.7 0.000
NRS in worst pain state 5.30±0.6 4.80±0.5 5.32±0.6 0.000
Satisfaction score 68.83±3.4 86.44±2.9* 82.81±2.7* 0.000
Side effect: N
Shivering 1/23 0/25 0/22 0.355
Nausea 4/23 5/25 3/22 0.846

Data were expressed as mean ± SD, median [interquartile ranges], or number of the patients (N).

R25: Perineural 0.25% ropivacaine with 15ml volume; MR: Perineural 200mg MgSO4 plus 0.25% ropivacaine with 15ml volume; R375: Perineural 0.375% ropivacaine with 15ml volume.

* P<0.01 indicates a significant difference in comparison to Group R25.

† P<0.05 indicates a significant difference in comparison to Group R25 and Group R375.